公开(公告)号：US11691981B2

公开(公告)日：2023-07-04

申请号：US16910878

申请日：2020-06-24

Applicant: INVENTISBIO CO., LTD.

Inventor： Xing Dai ,  Yaolin Wang ,  Yueheng Jiang ,  Yanqin Liu ,  Haotao Niu ,  Zhenwu Wang ,  Zixing Han ,  Liangshan Tao ,  Jifang Weng ,  Zhe Shi

IPC: C07D493/08 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D487/04

CPC classification number: C07D493/08 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D487/04

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

公开(公告)号：US11639344B2

公开(公告)日：2023-05-02

申请号：US17046621

申请日：2019-05-14

Applicant: INVENTISBIO CO., LTD.

Inventor： Xing Dai ,  Yueheng Jiang

IPC: C07D403/04 ,  A61K9/20 ,  A61K9/48

Abstract: Provided herein are compounds, salts, solid forms, and pharmaceutical compositions that are related to EGFR inhibitors, such as N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, solid forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as cancer.

公开(公告)号：US11241437B2

公开(公告)日：2022-02-08

申请号：US17172984

申请日：2021-02-10

Applicant: InventisBio Co., Ltd.

Inventor： Xing Dai ,  Yueheng Jiang ,  Yanqin Liu

IPC: C07D487/04 ,  A61K31/505 ,  A61P35/00 ,  A61K31/519 ,  A61K45/06 ,  C07D471/04

Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.